Instant Message-delivered Brief Internet-based Cognitive Behavioural Therapy (iCBT) for Post-stroke Depression
Launched by THE UNIVERSITY OF HONG KONG · May 28, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help stroke survivors who are experiencing depression. After a stroke, many people can feel sad or depressed, which can make their recovery harder and lead to more health issues. The study is testing a therapy called Internet-based Cognitive Behavioural Therapy (iCBT) delivered through instant messaging apps like WhatsApp and WeChat. The goal is to see if this method can effectively support stroke survivors in improving their mood and overall mental health.
To participate, individuals must be at least 18 years old, have had a stroke within the past year, and score between 5 to 19 on a depression screening test. They should also be able to read and communicate in Chinese and use messaging features on a smartphone. Participants will be divided into two groups: one will receive personalized support from a therapist through messaging for three months, while the other group will only get general mental health information. The study will measure how these different approaches help with depression and other aspects of mental well-being over six months. This research could provide valuable insights into new ways to support mental health for stroke survivors, particularly in Hong Kong and similar settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of stroke (ICD-10 codes: I60-I69);
- • Aged ≥18;
- • Able to read and communicate in Chinese (Cantonese or Putonghua);
- • Able to use the text or voice messaging function on smartphone;
- • MoCA 5-minute Protocol (cognitive screen) ≥14;
- • Community-dwelling
- • Less than 1 year after stroke event;
- • PHQ-9 (depressive symptom) score ranging from 5 to 19 (note. mild: 5-9, moderate: 10-14, moderately severe: 15-19 and severe: 20-27)
- Exclusion Criteria:
- • Diagnosis of psychiatric disease before stroke event or currently taking psychotropic drug including antidepressants
- • PHQ-9 ≥ 20 (i.e., severe depressive symptom)
- • Currently participating in any type of psychological intervention
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported